SI-BONE, Inc. 8K

SI-BONE, Inc. announced strong Q2 2026 results with higher revenue and adjusted EBITDA, operational and reimbursement tailwinds, and raised its full-year 2026 revenue and operating expense guidance.

SI-BONE, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting 15.2% year-over-year worldwide revenue growth to $56.0 million, an improved net loss of $4.1 million, positive adjusted EBITDA of $2.8 million, and positive operating cash flow, while also noting a 19% increase in its active U.S. physician base, the June submission of a 510(k) application for its third breakthrough device, and favorable CMS reimbursement changes for complex spinal fusion procedures incorporating iFuse Bedrock Granite effective October 1; based on these trends, the company raised its 2026 revenue guidance to a range of $231–$233 million, maintained gross margin guidance at ~79%, and modestly reduced expected operating expense growth.

Filing Facts

CIK

1459839

Ticker

-

Form

8K

Source Type

sec

Accession

0001459839-26-000066

Alert Tier

7